Prospects for Pharmaceutical Treatment of Achondroplasia
John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births. It arises from a defect in the process of bone growth in…
BioMarin
-
-
Study may change treatment of childhood growth disorders
A child’s growth is often measured by pediatricians during routine physicals to identify abnormalities of growth and stature. An abnormality in these measurements could mean a child has a growth…
-
BioMarin – Update for Achondroplasia Associations
As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the BioMarin clinical studies. The safety and well-being of study participants, healthcareproviders,…
-
BioMarin Announced Positive Final Results from Vosoritide Phase 3 pivotal trial. (BMN111-301)
BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide Placebo-adjusted Increase in Growth Velocity of 1.6 cm/yr (p<0.0001) in Children Treated with…
-
BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study
Company Plans to Provide Topline Phase 3 Data by Year End Company Presents Data Confirming that the Phase 3 and Phase 2 Study Participants have Similar Baseline Parameters SAN RAFAEL,…
-
BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type…
